Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism : the extended follow-up of the PROLONG study
Articolo
Data di Pubblicazione:
2009
Citazione:
Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism : the extended follow-up of the PROLONG study / B. Cosmi, C. Legnani, A. Tosetto, V. Pengo, A. Ghirarduzzi, A. Alatri, D. Prisco, D. Poli, A. Tripodi, G. Palareti. - In: JOURNAL OF THROMBOSIS AND THROMBOLYSIS. - ISSN 0929-5305. - 28:4(2009 Nov), pp. 381-388.
Abstract:
Background: The PROLONG study showed that D-dimer (D-d) testing could help tailor the duration of anticoagulation after idiopathic venous thromboembolism (VTE). In this report the initial 18 month study follow-up was extended for 1 year. Materials and Methods: D-d was measured 1 month after anticoagulation withdrawal for a first episode of idiopathic VTE. Patients with a normal D-d did not resume anticoagulation, while patients with an abnormal D-d were randomized to either resume or not resume treatment. The primary outcome was the composite of recurrent VTE and major bleeding. Secondary end-points were cardiovascular events, newly diagnosed cancers and deaths. Results: D-d was abnormal in 222/608 (36.5%) patients. Average follow-up was 2.55 years. Twenty-eight events occurred in the 121 patients who stopped anticoagulation (23.1%, 9.6% person-years) and five in the 101 patients who resumed anticoagulation (5.0%, 2.0% person-years, adjusted hazard ratio-HR = 3.76; P = 0.008). Recurrence rate was higher in patients with abnormal D-d who stopped anticoagulation than in patients with normal D-d (51 events in 386 patients -13.2%; 5% person-years; adjusted HR 1.70; P = 0.045). The adjusted HR ratio associated with normal D-d versus abnormal D-d in patients who resumed anticoagulation was 2.7 (P = 0.042). An abnormal D-d was associated with a non significant higher risk of cardiovascular events and newly diagnosed cancers vs normal D-d. Conclusions: Patients with an abnormal D-d at 1 month after withdrawal of VKA have a significant risk of recurrence over a 2.55 year follow-up and they benefit from resuming anticoagulation.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Cancer; Cardiovascular disease; D-dimer; Recurrence; Venous thromboembolism; Vitamin K antagonists
Elenco autori:
B. Cosmi, C. Legnani, A. Tosetto, V. Pengo, A. Ghirarduzzi, A. Alatri, D. Prisco, D. Poli, A. Tripodi, G. Palareti
Link alla scheda completa: